Tissue Regenix Group plc

('Tissue Regenix' or 'the Group')

Grant of share options

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that on 1 July 2025 Daniel Lee, Chief Executive Officer, was  granted an award of restricted share units ("RSU"), and Kirsten Lund, EMEA Business Director, was granted a Conditional Share Award (CSA), all with respect to ordinary shares in the capital of the Company ("Ordinary Shares") under the existing annual Tissue Regenix Share Incentive Plan following the publication of the 2025 annual report.

Daniel Lee has been awarded 428,711 RSU, and Kirsten Lund has been awarded 119,380 CSA, where each RSU/CSA that vests shall represent the right to receive payment of one Ordinary Share. The exercise price of the RSUs is 0.1p per Ordinary Share. The RSU/CSA are subject to continued service over a period of three years and satisfaction of customary performance conditions relating to growth in total shareholder return, annual revenue targets, annual profitability targets and personal performance targets (the "Options").

Following the grant of these Options, Daniel Lee hold options over a total of 1,078,135 RSU representing 1.53% of the current issued share capital respectively. Kirsten Lund holds options over a total of 305,176 CSA representing 0.43% of the current issued share capital.

For more information:

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation 'MAR' EU no.596/2014. Upon the publication of this announcement via the Regulatory Information Service 'RIS', this inside information is now considered to be in the public domain.

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.